arc-520
Nucleic acidexperimental
Clinical trial activity
9 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2013 (NCT01872065)
Timeline
Indications
Mechanism of action
- Hepatitis B virusANTISENSE INHIBITOR
Hepatitis B virus antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- arc-520
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02738008 | Phase 2 | Nov 1, 2016 | Arrowhead Pharmaceuticals |
| NCT02577029 | Phase 2 | Dec 1, 2015 | Arrowhead Pharmaceuticals |
| NCT02604212 | Phase 2 | Oct 1, 2015 | Arrowhead Pharmaceuticals |
| NCT02604199 | Phase 2 | Oct 1, 2015 | Arrowhead Pharmaceuticals |
| NCT02535416 | Phase 1 | Sep 1, 2015 | Arrowhead Pharmaceuticals |
| NCT02452528 | Phase 2 | Aug 1, 2015 | Arrowhead Pharmaceuticals |
| NCT02349126 | Phase 2 | Feb 1, 2015 | Arrowhead Pharmaceuticals |
| NCT02065336 | Phase 2 | Mar 1, 2014 | Arrowhead Pharmaceuticals, ICON |
| NCT01872065 | Phase 1 | Jul 1, 2013 | Arrowhead Pharmaceuticals, Nucleus Network Ltd |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | For profit | 9 | 9 | 2 | 2013 |
| ICON | For profit | 1 | 0 | 1 | 2014 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2013 |
3 organizations
Page 1 / 1